Published: May 17, 2021
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE)
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit. The presentation will be available on-demand starting at 8:00 AM ET on Friday, May 21, 2021.
A webcast of the presentation will be available for 90 days on the “IR Calendar” page within the Investors section of the Rezolute website at https://ir.rezolutebio.com/ir-calendar.
About Rezolute, Inc.
Rezolute is advancing novel therapies for diseases caused by chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in Phase 2b development for treatment of congenital hyperinsulinism (CHI), a rare pediatric endocrine disorder. The Company is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabeti
Errant Gene Therapeutics Becomes San Rocco Therapeutics
Errant Gene Therapeutics was founded in 1993, after founder Pat Girondi s son was diagnosed with Thalassemia, a cousin disease to Sickle Cell Anemia.
In 2007, with the help of researchers from Memorial Sloan Kettering, Cornell and National Institute of Health, EGT became the first entity to pass the FDA Recombinant DNA Committee for gene therapy in Sickle Cell Disease and Beta Thalassemia. EGT was the first company to get Orphan Drug Designation for Thalassemia in the US and Europe and first to produce a commercial batch (8-10 patients) of gene therapy for Sickle Cell Disease and Thalassemia. EGT is the company with the longest track record of treating US patients and the only company with experience in both harsh and soft chemotherapeutic prep-regimens.
PRA ‘toolkit’ pinpoints rare-disease clinical trial risks The free Patient-Centric Trial Development Toolkit is aimed toward helping sites and sponsors identify and minimize risks in rare-disease clinical studies.
PRA Health Sciences has launched its Patient-Centric Trial Development Toolkit, a resource designed to aid clinical trial teams in identifying risks that could stymie the effectiveness and efficiency of their research, and deal with those problems. Outsourcing-Pharma recently spoke with Scott Schleibner, senior vice president of the Center for Rare Diseases at PRA Health Sciences, about the toolkit, the unique challenges rare disease studies face, the importance of patient-centric trials, and more.
Affibody and Inmagene autoimmune partnership completes regulatory milestone Affibody and Inmagene Biopharmaceuticals report that the US FDA has cleared the interleukin-17 (IL-17) blocker, izokibep, to proceed to phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis.
Uveitis is an orphan disease with significant unmet medical need. It is an inflammation of the uveal tract but can also include the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. It is one of the leading causes of blindness worldwide.
Sweden’s Affibody and Inmagene, which has wholly owned subsidiaries in San Diego, Shanghai, and Hangzhou, are jointly developing izokibep, a novel bispecific agent, targeting both subunits of IL-17A as well as albumin, to treat multiple autoimmune diseases.
Περίπου 800 000 άνθρωποι στην Ελλάδα πάσχουν από μία Σπάνια Πάθηση naftemporiki.gr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from naftemporiki.gr Daily Mail and Mail on Sunday newspapers.